In humans, GDF15 has been found to be associated with MASLD [15] and GDF15 levels represent an independent determinant of fibrosis severity in MASLD; the more severe the chronic liver disease is, the higher the GDF15 levels are, apparently acting as a compensatory mechanism [30]. The gene discussed is GDF15; the disease is metabolic dysfunction-associated steatotic liver disease.